Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics is a U.S. biopharmaceutical company focused on medical dermatology and therapies for inflammatory skin conditions. Its research and commercial activities address immune-driven dermatologic diseases through targeted therapeutic mechanisms and formulation approaches suitable for different patient needs. The company is headquartered in Westlake Village, California, and its stock trades on Nasdaq under ARQT. Arcutis combines drug development, regulatory work and commercialization in dermatology, including approved therapies and investigational uses that may evolve over time.
Company at a glance
Corporate information
- Company entity
- Arcutis Biotherapeutics, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.arcutis.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: ARQT
targeted dermatology therapeutics · inflammatory pathways
dermatology · immune-mediated skin disorders
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Arcutis Biotherapeutics is a U.S. biopharmaceutical company focused on medical dermatology and therapies for inflammatory skin conditions. Its research and commercial activities address immune-driven dermatologic diseases through targeted therapeutic mechanisms and formulation approaches suitable for different patient needs. The company is headquartered in Westlake Village, California, and its stock trades on Nasdaq under ARQT. Arcutis combines drug development, regulatory work and commercialization in dermatology, including approved therapies and investigational uses that may evolve over time.
Business, technology & evidence
- SecuritiesNasdaq: ARQT
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Arcutis Biotherapeutics, Inc. ↗Arcutis Biotherapeutics, Inc. ·
- Official issuer and R&D disclosure · Arcutis Biotherapeutics, Inc. ↗Arcutis Biotherapeutics, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.